Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07338838 | To Evaluate the Tolerability and Pharmacokinetics of TQB3142 for Injection in Patients With Advanced Malignant Tumors | PHASE1 | NOT YET_RECRUITING | 66 | — | — | Jan 1, 2026 | Jun 1, 2028 | Jan 14, 2026 | 2 | China |
The dosage of drug therapy recommended for use in the second phase of clinical trials (i.e., phase II clinical trials).
Adverse events that meet the protocol definition of dose-limiting toxic event timing were evaluated according to the Common Terminology Criteria for Adverse Events 5.0.
The previous dose of the dose group in which dose-limiting toxicity occurs is the maximum tolerated dose.
| Arm | Type | Description |
|---|---|---|
| TQB3142 injection | EXPERIMENTAL | The drug was administered every weeks for 28 consecutive days in a treatment cycle. |
| Name | Type | Description |
|---|---|---|
| TQB3142 injection | DRUG | TQB3142 for injection is a B-cell lymphoma-extra large inhibitor. |
Inclusion Criteria: * The subjects voluntarily joined the study, signed the informed consent, and had good compliance; * 18 years old ≤ age ≤75 years old (calculated on the date of signing the informed consent); * Eastern Cooperative Oncology Group Performance Status (ECOG) score 0\~1; * Expected s...